- Home
- ARR vs CRGX Comparison
ARR vs CRGX Comparison
Compare ARR & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARR
- CRGX
- Stock Information
- Founded
- ARR 2008
- CRGX 2021
- Country
- ARR United States
- CRGX United States
- Employees
- ARR N/A
- CRGX N/A
- Industry
- ARR Real Estate Investment Trusts
- CRGX
- Sector
- ARR Real Estate
- CRGX
- Exchange
- ARR Nasdaq
- CRGX Nasdaq
- Market Cap
- ARR 1.0B
- CRGX 964.5M
- IPO Year
- ARR N/A
- CRGX 2023
- Fundamental
- Price
- ARR $18.44
- CRGX $15.82
- Analyst Decision
- ARR Hold
- CRGX Strong Buy
- Analyst Count
- ARR 3
- CRGX 7
- Target Price
- ARR $19.75
- CRGX $30.33
- AVG Volume (30 Days)
- ARR 2.1M
- CRGX 187.0K
- Earning Date
- ARR 10-23-2024
- CRGX 11-12-2024
- Dividend Yield
- ARR 15.69%
- CRGX N/A
- EPS Growth
- ARR N/A
- CRGX N/A
- EPS
- ARR 2.41
- CRGX N/A
- Revenue
- ARR $185,086,000.00
- CRGX N/A
- Revenue This Year
- ARR N/A
- CRGX N/A
- Revenue Next Year
- ARR $20.70
- CRGX N/A
- P/E Ratio
- ARR $7.66
- CRGX N/A
- Revenue Growth
- ARR N/A
- CRGX N/A
- 52 Week Low
- ARR $16.79
- CRGX $13.56
- 52 Week High
- ARR $21.93
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- ARR 32.23
- CRGX 32.43
- Support Level
- ARR $18.42
- CRGX $15.46
- Resistance Level
- ARR $18.91
- CRGX $23.00
- Average True Range (ATR)
- ARR 0.40
- CRGX 1.61
- MACD
- ARR -0.00
- CRGX -0.67
- Stochastic Oscillator
- ARR 20.45
- CRGX 6.87
About ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.